Navigation Links
Vermillion Presents Critical Data From Its OVA1 Clinical Trial
Date:2/10/2009

Study Presented at Society of Gynecologic Oncologists' 40th Annual Meeting - on Women's Cancer

FREMONT, Calif., Feb. 10 /PRNewswire-FirstCall/ -- Vermillion, Inc. (OTC Bulletin Board: VRML), a molecular diagnostics company, presented data from its prospective OVA1 clinical trial at the Society of Gynecologic Oncologists' (SGO) 40th Annual Meeting on Women's Cancer in San Antonio, TX (Poster 196). The study entitled "A biomarker panel for distinguishing between malignant and benign ovarian tumors" was co-authored by Fred Ueland, MD, Associate Professor of Gynecologic Oncology at the University of Kentucky and Principal Investigator of the OVA1 clinical trial, and Zhen Zhang, PhD, Associate Professor of Pathology at the Johns Hopkins University School of Medicine as well as Vermillion scientists.

Details of the poster are available in the attached link "A biomarker panel for distinguishing between malignant and benign ovarian tumors." The primary aim of the study was to determine the ability of our proprietary OvaCalc algorithm to estimate the risk of malignancy in pre and postmenopausal women who are scheduled for surgery with an ovarian mass. The data demonstrates that the OvaCalc algorithm can effectively identify women with a higher likelihood of malignancy. Within the study population, the OvaCalc algorithm also detected 90% of Stage I epithelial ovarian cancer cases and 100% of stage 2-4 cancers while maintaining a greater than 90% negative predictive value among both premenopausal and postmenopausal patients.

"We are extremely pleased with the significant results of the OVA1 prospective clinical trial. A major strength of the OVA1 prospective clinical trial was its inclusion of patients seen at a variety of clinical settings where the inten
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
2. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
3. Vermillion and the Ohio State University Report That Novel Diagnostic Test May Help Predict Risk for Relapse of TTP, A Serious Blood Disorder
4. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
5. Vermillion Receives Award From the Society of Gynecologic Oncologists
6. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
7. EntreMed Presents Initial Clinical Results for ENMD-2076
8. Access Pharmaceuticals Presents new Combination Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
9. Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia
10. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
11. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  IGI Laboratories, Inc. (NYSE ... closing of its offering of $125 million aggregate principal ... "Notes").  The Notes were offered and sold only to ... Securities Act of 1933, as amended (the "Securities Act"). ... rate of 3.75% per year, payable semiannually in arrears ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 17, 2014 ... and Integrated Clinical Trial Services, LLC (ICTS), two ... clinical trials announce that they have formed a ... (i-CTMS). i-CTMS will provide a broad range of ... and medical device companies. i-CTMS will ...
(Date:12/15/2014)... 15, 2014 Registreer nu via  ... und 20. Februar sind alle akkreditierten pharmazeutischen ... ECOSYSTEM PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, der ... die neue profitablen Unternehmensdienstleistungen, die für Apotheken ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... STXS ) today announced that executive management will ... The Deutsche Bank Annual Health Care Conference in ... Stereotaxis, is scheduled to present an overview of the Company ... The JMP Securities Annual Research Conference in San Francisco.  Daniel ...
... StreamVenue Healthcare has partnered its "plug ... for Surgery At Presbyterian Hospital Dallas to foster ... StreamVenue Healthcare rolled out this year its Solution ... technology. The package includes EndoCom hardware; StreamingOR, live ...
Cached Medicine Technology:Stereotaxis to Present at Upcoming Investor Conferences 2Stereotaxis to Present at Upcoming Investor Conferences 3StreamVenue Healthcare Pacing Future of Endoscopy Technology 2
(Date:12/15/2014)... Reinberg HealthDay Reporter FRIDAY, ... should reassure the millions of American women who have migraine: ... "There is no association between migraine and breast cancer ... medicine at Harvard Medical School. "There is no positive association, ... no protective effect either." About 18 percent of American ...
(Date:12/15/2014)... December 15, 2014 The increase in prevalence ... of the main factors which is contributing to the growth ... the diagnosis and treatment of hearing loss and balance disorders ... three parts - microphone, speaker and amplifier. The global market ... of 6.01% during the period from 2014 to 2019. Some ...
(Date:12/15/2014)... 15, 2014 Emergo Group, Inc., a ... countries in North and South America, Europe, the Middle ... industry participants for its 2015 Medical Device Industry Survey. ... identify upcoming business and market trends as well as ... survey targets areas including:, , Overall ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 At the ... organizations AutismOne and Focus Autism ... attendees with research on the effects of toxins to ... and intervention information. , Luminaries such as Dr. ... from abroad with esteemed, credentialed colleagues of the United ...
(Date:12/15/2014)... Kenmode Precision Metal Stamping has announced that Abid ... Assurance. He brings more than 15 years of ... manufacturers in the U.S. and abroad. , He ... Sonoco Products Company in the Protective Solutions Division, Vice ... Manager for Prince Industries, all in the Chicago area. ...
Breaking Medicine News(10 mins):Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3Health News:Kenmode Precision Metal Stamping Appoints Abid Rashid as Director of Quality Assurance 2
... CVS Caremark (NYSE: CVS ) announced ... again been recognized for customer satisfaction excellence by ... This is the third time that the Company ... center operations as providing "An Outstanding Customer Service ...
... CYBX ) today announced that the company will ... 2009 of its fiscal year ending April 24, 2009 on ... company will conduct a conference call to discuss those results ... Fiscal Year 2009 Third Quarter Results Conference Call Instructions ...
... Workouts counter functional decline, could ward off osteoarthritis, ... News) -- Exercise may play a key role ... and knee osteoarthritis (OA), two new studies show. ... following a six-week progressive strengthening program showed much ...
... cause of death with over 6 million new cases worldwide ... of cancer are diagnosed annually, and half a million Americans ... years of research, GlycoMeds ( http://www.cancer-test-kits.com ) has released the ... a way to detect it in the early stages when ...
... investigation into the shooting death of American video-journalist Brad Will has ... the discovery that one of the bullets was a ricochet. ... ... Physicians for Human Rights (PHR) charges that Mexico,s investigation into ...
... Through 2017 for Relapsing-Remitting Multiple Sclerosis, According to ... 4 Decision Resources, one of the world,s ... healthcare issues, finds that an oral disease-modifying therapy ... percent patient share in Europe and a 40 ...
Cached Medicine News:Health News:Caremark Customer Care Centers Recognized for Customer Satisfaction Excellence by J.D. Power and Associates Certified Call Center Program(SM) 2Health News:Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 Third Quarter Financial Results 2Health News:Exercise Key Player in Knee Replacement Recovery 2Health News:GlycoMeds Discovery Yields Early Warning Test for Cancer 2Health News:Mexico Presents Flawed Theory in Shooting Death of American Journalist 2Health News:Mexico Presents Flawed Theory in Shooting Death of American Journalist 3Health News:Mexico Presents Flawed Theory in Shooting Death of American Journalist 4Health News:An Oral Disease-Modifying Drug for Relapsing-Remitting Multiple Sclerosis Would Earn High Patient Shares in Both Europe and the United States 2Health News:An Oral Disease-Modifying Drug for Relapsing-Remitting Multiple Sclerosis Would Earn High Patient Shares in Both Europe and the United States 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: